Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications

Abstract Background Lenvatinib, a tyrosine kinase receptor inhibitor, has emerged as a frontline therapeutic strategy for the management of advanced hepatocellular carcinoma (HCC). However, the modest response rate observed with lenvatinib and the rapid emergence of chemoresistance highlight the urg...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bixing Zhao, Yang Zhou, Niangmei Cheng, Xiaoyuan Zheng, Geng Chen, Xin Qi, Xiangzhi Zhang, Fei Wang, Qiuyu Zhuang, Yehuda G. Assaraf, Xiaolong Liu, Yingchao Wang, Yongyi Zeng
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-05-01
Col·lecció:	Journal of Experimental & Clinical Cancer Research
Matèries:	Hepatocellular carcinoma Lenvatinib Resistance PDGFRA Avapritinib
Accés en línia:	https://doi.org/10.1186/s13046-025-03386-8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!